U.S. Markets closed
  • S&P 500

    3,662.45
    +40.82 (+1.13%)
     
  • Dow 30

    29,823.92
    +185.28 (+0.63%)
     
  • Nasdaq

    12,355.11
    +156.37 (+1.28%)
     
  • Russell 2000

    1,836.05
    +16.23 (+0.89%)
     
  • Crude Oil

    44.40
    -0.94 (-2.07%)
     
  • Gold

    1,813.90
    +38.20 (+2.15%)
     
  • Silver

    24.06
    +1.52 (+6.75%)
     
  • EUR/USD

    1.2074
    +0.0140 (+1.1712%)
     
  • 10-Yr Bond

    0.9340
    +0.0900 (+10.66%)
     
  • Vix

    20.77
    +0.20 (+0.97%)
     
  • GBP/USD

    1.3429
    +0.0097 (+0.7305%)
     
  • USD/JPY

    104.3100
    -0.0140 (-0.0134%)
     
  • BTC-USD

    19,153.40
    -246.36 (-1.27%)
     
  • CMC Crypto 200

    375.95
    -3.91 (-1.03%)
     
  • FTSE 100

    6,384.73
    +118.54 (+1.89%)
     
  • Nikkei 225

    26,787.54
    +353.92 (+1.34%)
     

4 Stocks Looking Higher During Earnings Season

Harry Boxer - TheTechTrader.com

By Harry Boxer, TheTechTrader

Here are three health stocks and one technology stock that are at or near key breakout points:

Clovis Oncology, Inc. (NASDAQ: CLVS) popped 90 cents, or more than 10%, to $9.73 on 11.7 million shares Wednesday on no news. The move edged the stock out of a declining wedge pattern it's been in since its December top. A break through moving average resistance near $10.45 and then the recent double-top at $11.15-.25 could lead the stock to $13 next.

3D Systems Corporation (NYSE: DDD) climbed 63 cents, or 5.3%, to $12.34 on 2.9 million shares Wednesday. On Monday, the company announced an expanded relationship with Sanmina to manufacture certain plastic 3D printing platforms. Wednesday's move broke the stock out of a month-long wedge formation, and next resistance for the stock, which has nearly doubled in 5 months, is at $14.25.

Fulgent Genetics, Inc. (NASDAQ: FLGT) jumped $1.52, or 10.9%, to $15.42 on 458,900 shares Wednesday. The move, which came on no news from the genetic testing services company, broke the stock out of a 3-month coil. If it can get through lateral resistance right near here in the $15.50 zone, the near-term target is the $16.50 high from November, with the mid-channel target at $18.50.

Mallinckrodt plc (NYSE: MNK) gained 31 cents, or 6.4%, to $5.14 on 6.1 million shares Wednesday on no news from the specialty pharmaceutical company. The stock, which broke out a base in January and had an orderly pullback from resistance on lower volume, has been picking up in the last two sessions, and looking poised to re-test the highs. Initial target is $7.

See Harry's video chart analysis on these stocks.

No holdings.

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.

Image Sourced from Pixabay

0

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.